Novartis Receives Swissmedic Approval for Cosentyx
Published: Monday, Aug 14th 2023, 08:40
Aktualisiert am: Freitag, 13. Oktober 2023, 14:12
Zurück zu Live Feed
Novartis has received Swissmedic approval for Cosentyx for the treatment of adults with active moderate to severe Hidradenitis suppurativa (HS). Clinical Phase-III study data has shown that Cosentyx leads to long-lasting clinically relevant improvements in symptoms, Novartis announced on Monday. On 10 August, Swissmedic approved Cosentyx for the treatment of HS. HS is a severely debilitating chronic skin condition that can lead to irreversible tissue destruction. In Switzerland, approximately one percent of the adult population is affected by the condition. For the approval, Swissmedic relied on the results of two global Phase-III programs for HS (SUNSHINE and SUNRISE). The safety results corresponded to the safety profile of Cosentyx in the already eight approved indications. Novartis has received Swissmedic approval for Cosentyx for the treatment of adults with active moderate to severe Hidradenitis suppurativa (HS). Clinical Phase-III study data has shown that Cosentyx leads to long-lasting clinically relevant improvements in symptoms. HS is a severely debilitating chronic skin condition that can lead to irreversible tissue destruction, affecting approximately one percent of the adult population in Switzerland. Swissmedic approved Cosentyx based on the results of two global Phase-III programs for HS (SUNSHINE and SUNRISE). The safety results corresponded to the safety profile of Cosentyx in the already eight approved indications.nnnnnnnn
©Keystone/SDA
German 
English 
French 
Spanish 
Arabic